Bladder Cancer Research Initiative for Drug Targets 

The BRIDGE Consortium is a non-profit, interdisciplinary association of urologists, oncologists, pathologists and basic scientists who pool their expertise to advance the research and treatment of patients with bladder cancer.

The aim is to develop innovative, translational therapeutic approaches through the networking of independent institutions and specialist disciplines and to research and promote these as part of clinical studies. The aim is to actively and neutrally coordinate scientific projects and transfer basic scientific findings into clinical practice.

A particular focus is on the testing of novel test systems that can help to clarify the pathogenesis of bladder cancer and accelerate specialized, individualized therapy. The BRIDGE Consortium e.V. sees itself as a platform for pooling clinical and scientific expertise and as a driving force for new scientific approaches and collaborations.

Our aim is to actively and independently promote the further development of treatment strategies for bladder cancer and to support interdisciplinary initiatives within the existing network. The exchange and transfer of knowledge about various aspects of bladder cancer are central elements of our network. In this way, we aim to build a bridge between clinical institutions, university research, foundations, non-profit organizations and the pharmaceutical industry - “from bench to bedside”.